Institutional Repository of Xishuangbanna Tropical Botanical Garden
Drug evaluation: Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer | |
Newman, S | |
2007 | |
Source Publication | CURRENT OPINION IN INVESTIGATIONAL DRUGS
![]() |
ISSN | 1472-4472 |
Volume | 8Issue:12Pages:1057-1066 |
Abstract | Eisai Co Ltd is developing eribulin, a simplified synthetic macrocyclic ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Phase III trials are underway in the US and Europe for patients with breast cancer. Eribulin is currently in phase II trials for NSCLC and soft tissue sarcoma, and pancreatic, prostate, ovarian, fallopian tube, peritoneal and head and neck cancer, and phase I/II trials for urothelial cancers. |
Keyword | Human Breast-cancer Multidrug-resistance Practical Synthesis Natural-products P-glycoprotein Solid Tumors In-vitro Expression Mechanism Segment |
Language | 英语 |
Document Type | 期刊论文 |
Identifier | https://ir.xtbg.ac.cn/handle/353005/10248 |
Collection | 文献共享 |
Recommended Citation GB/T 7714 | Newman, S. Drug evaluation: Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer[J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS,2007,8(12):1057-1066. |
APA | Newman, S.(2007).Drug evaluation: Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.CURRENT OPINION IN INVESTIGATIONAL DRUGS,8(12),1057-1066. |
MLA | Newman, S."Drug evaluation: Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer".CURRENT OPINION IN INVESTIGATIONAL DRUGS 8.12(2007):1057-1066. |
Files in This Item: | Download All | |||||
File Name/Size | DocType | Version | Access | License | ||
Eribulin, a simplifi(6742KB) | 开放获取 | CC BY-NC-SA | View Download |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment